Jim Hopper, PhD, is a Teaching Associate in Psychology at Harvard Medical School, where he co-directs a conference on psychedelic-assisted psychotherapy. With over 25 years of experience as a clinical psychologist, therapist, and independent forensic consultant for MAPS, he focuses on the psychological and neurobiological effects of trauma, including sexual assault and child abuse. Jim has provided training and consultation to therapists, law enforcement, military personnel, and higher education administrators and has served as an expert witness in legal cases.

Many clinicians entering the field of psychedelic-assisted psychotherapy assume that the medicine alone drives healing, overlooking the critical role of the therapeutic relationship. Without a strong relational foundation, clients can experience retraumatization, disempowerment, or even harm during these vulnerable states. How can practitioners create safe, empowering, and effective therapeutic environments during psychedelic-assisted psychotherapy?

As a clinical psychologist specializing in trauma and psychedelic-assisted psychotherapy, Jim Hopper advises clinicians to combine empowerment, connection, and attunement during psychedelic therapy sessions. He advocates for trauma-informed care that supports client autonomy and competence while maintaining a genuine relational connection. Preparation, integration, and an awareness of relational dynamics like transference and countertransference are essential components of the psychedelic therapy process. By maintaining faith in the client’s inner healing wisdom, therapists can help clients feel safe, empowered, and supported throughout their healing journeys.

In this week’s episode of Living Medicine, Dr. Sandy Newes interviews Jim Hopper, PhD, Teaching Associate at Harvard Medical School, about creating safe and relational psychedelic-assisted psychotherapy sessions. Jim talks about balancing autonomy and competence, avoiding therapist overreach, and the risks of replicating trauma dynamics in therapy.

Rick Doblin, PhD, is the Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), a nonprofit organization advancing research into the therapeutic potential of psychedelics. He studied under Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. Rick aims to develop legal contexts for the beneficial uses of psychedelics and marijuana.

The path to healing trauma and advancing mental health care through psychedelic therapies is often blocked by regulatory barriers, cultural stigma, and skepticism. While MDMA-assisted psychotherapy shows immense promise, therapists wonder how these treatments can be made widely accessible and trusted, especially across different cultures, age groups, and medical systems. What does it take to shift public perception and institutional acceptance?

Psychedelic researcher and therapy pioneer Rick Doblin combines rigorous clinical research, international therapist training, and grassroots cultural change to reduce the stigma surrounding psychedelic therapies. He has initiated humanitarian projects in high-trauma, low-resource regions like Ukraine and Rwanda and facilitated the FDA approval process through pilot studies and collaborative research. Rick emphasizes the importance of therapist training — including firsthand MDMA experience — and encourages public storytelling to destigmatize psychedelics and build broader support.

In today’s episode of Living Medicine, Dr. Sandy Newes welcomes Rick Doblin, PhD, Founder and President of MAPS, to discuss his pioneering research into MDMA and other psychedelic-assisted psychotherapies. Rick talks about group and family psychedelic therapy models, the relationship between mysticism and therapeutic outcomes during psychedelic sessions, and how to support natural emotions during vulnerable states.

Dr. Erika Czerwinski, PsyD, is the Founder, Director, and Facilitator of Eleos, which integrates ketamine-assisted psychotherapy and nature-based mindfulness to facilitate self-discovery. With over 20 years of clinical experience working with individuals, couples, and groups, Dr. Czerwinski holds certifications in psychedelic-assisted therapies from MAPS, the Integrative Psychiatric Institute, and the Living Medicine Institute. Since 2019, she has facilitated ketamine-assisted psychotherapy for physicians, young adults, and those healing from trauma.

As the psychotherapy space enters a psychedelic renaissance, navigating the complex relational dynamics that emerge in altered states remains a top concern. How can therapists maintain ethical boundaries while being authentic and responsive during such vulnerable moments? What role do clinical frameworks like attachment theory and transference play when working with powerful medicines like ketamine?

According to clinical psychologist Dr. Erika Czerwinski, relational attunement, psychoanalytic listening, and ceremony-based approaches can ground and enrich ketamine-assisted psychotherapy. Distinguishing dosages helps clinicians tailor interventions based on client needs and internal states. When clients begin regaining verbal awareness during ketamine sessions, gentle, well-timed reflections can surface unconscious material, validate emerging emotional experiences, and help anchor insights for integration. By attuning to transference patterns and unconscious processes, interpretations can deepen relational safety and accelerate healing.

In this episode of Living Medicine, Dr. Sandy Newes interviews Erika Czerwinski, PsyD, Founder, Director, and Facilitator of Eleos, about integrating relational depth into psychedelic-assisted psychotherapy. Dr. Czerwinski talks about working with clients experiencing personality disorders, the difference between psychedelic and psycholytic therapy sessions, and how ketamine compares to similar psychedelics in clinical usage.

Dissociative identity disorder (DID) is often misunderstood, stigmatized, or misdiagnosed, especially in high-functioning individuals who mask symptoms through adult-like coping strategies. Many live for decades without a clear diagnosis, struggling silently with memory gaps, emotional volatility, and identity confusion. How can modern therapeutic practices like psychedelic-assisted psychotherapy identify and support people navigating this complex condition?

Today’s guest struggled for years with DID that remained hidden behind a facade of accomplishments until various life stressors made symptoms unavoidable. Through intensive trauma therapy and psychedelic-assisted psychotherapy, they identified distinct parts within themself, recognized their trauma origins, and began the integration process. The guest emphasizes that psychedelics allow access to vivid trauma memories, the role of the therapist in creating safety and attunement during complex trauma work, and how gaining agency over their identities transformed their condition from a burden into a strength.

Join Dr. Signi Goldman in today’s episode of Living Medicine as she recounts an interview with an anonymous client about resolving DID through psychedelic-assisted psychotherapy. The guest talks about identifying and healing distinct internal identities, their early experience with DID symptoms, and how somatic touch can facilitate identity reconciliation.

Dr. Phil Wolfson, MD, is the Founder and CEO of the Ketamine Research Foundation, which advances ketamine’s use in therapeutic modalities. As a pioneering psychiatrist and psychotherapist, he is the author of The Ketamine Papers and Noe – A Father/Son Song of Love, Life, Illness and Death. Dr. Wolfson served as the Principal Investigator for a MAPS-sponsored Phase 2 clinical trial exploring MDMA-assisted psychotherapy for patients with anxiety from life-threatening illnesses.

As psychedelic-assisted therapies become more mainstream, ketamine treatments are increasingly medicalized, often lacking the integration, connection, and context that can unlock their true healing potential. How can clinicians ensure these therapies are transformative rather than transactional?

Psychedelic psychotherapist Dr. Phil Wolfson advises against separating ketamine from psychotherapy. Instead, he advocates for an integrative, human-centered approach that includes preparatory work, therapist presence, and post-session integration. When determining patient dosage, clinicians should focus on assessing the individual rather than adhering to rigid protocols. Dr. Wolfson also urges clinicians to cultivate compassion, deepen their therapeutic relationships, and consider the spiritual and emotional dimensions of healing, especially when working with trauma and grief.

In this episode of Living Medicine, Dr. Sandy Newes talks with Dr. Phil Wolfson, the Founder and CEO of the Ketamine Research Foundation, about the art and ethics of ketamine-assisted psychotherapy. Dr. Wolfson shares how his son’s illness led him to pursue psychedelic-assisted psychotherapy, consciousness and death in psychedelic experiences, and the contrast between IV clinics and integrative therapy models.

Dr. Jonathan Leake is a Board Certified Emergency Department Physician and the Co-owner and CEO of Dérive Health, a clinic specializing in ketamine-assisted therapy for PTSD, depression, and other treatment-resistant mental health conditions. With over a decade of experience treating dehydration and illness with IV fluids and medications, Dr. Leake also co-founded Hydrate Medical, which administers IV vitamin infusions. He is certified in psychedelic-assisted therapy from the California Institute of Integral Studies (CIIS) and MAPS and holds a certification in ketamine therapy from the Living Medicine Institute.

Many physicians are burned out by the limitations of traditional medicine, especially when treating mental health crises in high-pressure environments like the ER. While they may feel called to do more, the pathway to practicing psychedelic therapy can seem unclear and overwhelming. How can medical professionals transition into ketamine-assisted care?

After noticing a lack of effective treatment for mental health conditions, emergency medicine physician and ketamine clinician Dr. Jonathan Leake transitioned from the ER to providing ketamine therapy. Ketamine therapy requires maintaining supportive care throughout each treatment session, so physicians must build patient rapport, assess and manage the environment’s energy, and recognize psychological vulnerability. When treating patients with complex trauma, Dr. Leake advises physicians to recognize the limits of their training and partner closely with licensed therapists who can guide a deeper therapeutic process.

In this episode of Living Medicine, Dr. Jonathan Leake, the Co-owner and CEO of Dérive Health, joins Dr. Sandy Newes to discuss how physicians can provide ketamine therapy. He highlights the importance of patient care during ketamine therapy sessions, insights from various psychedelic therapy conferences, and the role of training in physician performance.

Trauma from sudden medical crises often leaves more than physical scars; it disrupts a person’s sense of safety, identity, and control. Traditional therapy can feel too slow or disconnected when your body and mind are flooded with fear. When even the memory of being in a hospital is too much to bear, how can you move forward?

One resilient woman turned to ketamine-assisted psychotherapy to process acute medical trauma. The guided sessions allowed for deep internal work — accessing and dialoguing with younger, traumatized parts of herself in a safe, altered state. Having a trusted therapist present, repeating her words and prompting her to explore further, helped anchor the experience. This inner self work, paired with a sense of physical and emotional safety, became essential for healing, especially after difficult sessions that re-triggered memories. The guest emphasizes the value of entering the sessions with an open mind and the importance of having a supportive therapeutic relationship.

In this episode of Living Medicine, Dr. Signi Goldman hears from an anonymous client about her experience with ketamine-assisted psychotherapy for acute medical trauma. Together, they explore how medical trauma affects the nervous system, tips for first-time ketamine therapy patients, and how to release tension and embrace safety during ketamine-assisted psychotherapy sessions.

Veronika Gold, LMFT, is the Co-founder of Polaris Insight Center, a clinic offering ketamine-assisted psychotherapy, integrative psychiatry, and integration services. She is a lead trainer at Polaris Training Program. She served as a sub-investigator and co-therapist, educator, and consultant at the Lykos clinical trials for the treatment of PTSD with MDMA-assisted psychotherapy. As a licensed marriage and family therapist, Veronika specializes in treating trauma, anxiety, stress, transition, self-esteem, employment, and relationship issues.

Too often, psychedelic-assisted therapy is reduced to a clinical buzzword or a quick-fix intervention, stripping it of the depth and relational care it requires. As more people seek healing through non-ordinary states, there's growing confusion — and sometimes harm — caused by untrained providers and disjointed treatment models. What does it take to offer safe, ethical, and transformative psychedelic-assisted therapy?

With deep experience in trauma work and non-ordinary states, Veronika Gold emphasizes the importance of a strong therapeutic relationship, proper training, and personal experience with psychedelics. Ketamine treatment without therapeutic intervention can cause lasting damage, so Veronika advocates for relational, trauma-informed care that honors consent, somatic awareness, and integration over time. Rather than rushing to gain the patient’s insights during ketamine therapy sessions, therapists should remain cautious and curious, integrating somatic intervention techniques as needed.

In this week’s episode of Living Medicine, Dr. Sandy Newes hears from Veronika Gold, LMFT, the Co-founder of Polaris Insight Center, who talks about trauma-informed psychedelic therapy. Veronika shares her perspective on the role of non-ordinary states in healing, the distinction between MDMA and ketamine-assisted psychotherapy, and how she uses therapeutic touch during psychedelic therapy sessions.